VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. White on Ablative Radiotherapy for MBC

Julia White, MD
Published: Friday, Mar 14, 2014

Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the use of ablative radiotherapy in patients with metastatic breast cancer.

White says an ablative radiotherapy approach to metastatic regions allows a patient to not have to undergo a surgical procedure. Even though surgical procedures are typically well tolerated, there are inherent risks of both anesthesia and complications following surgery.

When metastatic breast cancer patients have to undergo surgery, they have to stop systemic therapy, White says, which interrupts the treatment process. With an ablative radiotherapy approach, there are no treatment interruptions.

Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the use of ablative radiotherapy in patients with metastatic breast cancer.

White says an ablative radiotherapy approach to metastatic regions allows a patient to not have to undergo a surgical procedure. Even though surgical procedures are typically well tolerated, there are inherent risks of both anesthesia and complications following surgery.

When metastatic breast cancer patients have to undergo surgery, they have to stop systemic therapy, White says, which interrupts the treatment process. With an ablative radiotherapy approach, there are no treatment interruptions.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x